Gilgamesh Pharma (United States)

Homepage: gilgameshpharmaceutical.com

Alternate names: Gilgamesh Pharma, Gilgamesh Pharma, Inc., Gilgamesh Pharmaceuticals

ROR: 03yv14779

OpenAlex ID: I4405267702

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

2023 · Jason Wallach, Andrew B. Cao, et al. · Nature Communications · 207

Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review

2021 · Marla C. Dubinsky, Iris Dotan, et al. · Expert Review of Gastroenterology & Hepatology · 97

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers

2023 · M. Cecchi, M. Adachi, et al. · Schizophrenia Research · 28

GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents

2024 · Adam K. Klein, Eric W. Austin, et al. · Neuropsychopharmacology · 15

An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice

2026 · Connor J. Maltby, Adam K. Klein, et al. · Journal of Psychopharmacology · 9

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B receptor, and morphine in recreational opioid users

2023 · Mototsugu Ito, Mark Walzer, et al. · Journal of Psychopharmacology · 5

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder

2023 · Mototsugu Ito, Mark Walzer, et al. · Journal of Psychopharmacology · 4

A novel psychedelic 5-HT 2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

2025 · Gerard J. Marek, Soma Makai-Bölöni, et al. · Journal of Psychopharmacology · 3

Testosterone and 17β-estradiol regulate hippocampal area CA3 sharp waves in male and female rats

2025 · Patrice Pearce, John J. LaFrancois, et al. · Cell Reports · 3

Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice

2025 · Michael Noback, Johnny A. Kenton, et al. · Neuropharmacology · 3

22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy

2023 · Zoe Hughes, Adam Klein, et al. · Biological Psychiatry · 1

355. Antidepressant Efficacy of Blixeprodil (GM-1020), a Novel, Orally Administered NMDA Receptor Antagonist, in a Double-Blind, Randomized, Placebo-Controlled Study in Patients With Major Depressive Disorder

2026 · Gerard Marek, Jorge Quiroz, et al. · Biological Psychiatry

First-in-human pharmacological characterization of the novel NMDA receptor antagonist GM-1020: a single ascending dose study in healthy participants

2026 · S. Makai-Boloni, G. Marek, et al. · Neuroscience Applied

Pharmacokinetic, pharmacodynamic and subjective and effects of the novel 5-HT2A receptor agonist GM-2505 in healthy volunteers

2024 · D. Umbricht, E. Christian, et al. · Neuroscience Applied

527. GM-2040 is a Novel Putative Non-Hallucinogenic 5-HT2A Agonist With Attenuated Head Twitch and Retained Antidepressant Activity

2023 · Adam Klein, Eric Austin, et al. · Biological Psychiatry

531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine

2023 · Adam Klein, Dino Dvorak, et al. · Biological Psychiatry

Works count: 16

Citation count: 574